VIMTALABS2026-04-012026-06-30VIMTALABS2026-04-012026-06-30in-capmkt:OtherExpenses1MemberVIMTALABS2026-04-012026-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares524394VIMTALABSNOTLISTEDINE579C01029Vimta Labs LimitedMain BoardEquity2026-04-012027-03-312026-07-202026-07-15INRMillionsQuarterlyFirst quarterSingle segmentCONTRACT RESEARCH AND TESTING SERVICES2026-07-2010:30:002026-07-2013:30:00Not applicablefalsefalseNot Applicable.2026-04-012026-06-30UnauditedStandalone1090740000381200001128860000226720000002942000002370000125480000196710000845480000283380000028338000058520000144400007296000002104200000000210420000-1500002102700008934000024.714.66004.714.661.The above Unaudited financial results for the quarter ended June 30, 2026 have been reviewed and recommended by the Audit Committee and approved by the Board in its meeting held on July 20, 2026. <br /> 2.The results for the quarter ended June 30, 2026 were subjected to Limited Review by the statutory auditors of the company. An unmodified report was issued by them thereon. <br /> 3.These Unaudited financial results have been prepared in accordance with the Indian Accounting Standards (IND AS) prescribed under section 133 of the Companies Act, 2013 (the Act) read with relevant rules issued thereunder and other accounting principles generally accepted in India and the guidelines issued by the Securities and Exchange Board of India (SEBI) in this regard. <br /> 4.The management has assessed the identification of reportable segments in accordance with the requirements of Ind AS-108 Operating Segment and stated that the Company has only one reportable segment namely Contract Research and Testing Services. <br /> 5.The company had entered into a Public Private Partnership (PPP) agreement with Food Safety and Standards Authority of India (FSSAI) on June 29, 2021 to setup, operate and transfer (SOT) a National food Testing Laboratory (NFL) in JNPT,Mumbai. In accordance with the provisions of Ind AS 115, this arrangement has been considered as a Service Concessionaire Arrangement (SCA) and accordingly, revenue and costs are allocatable between those relating to lab setup services and those relating to operation and maintenance services. Further, the Company has acquired the right to charge the customer for the services to be rendered which has been assessed as an intangible asset. <br /> Revenue from operations and lab setup expenses include Rs. 0.45 million for the quarter ended June 30, 2026, Rs. 0.27 million for the quarter ended March 31, 2026, Rs. 0.11 million for the quarter ended June 30, 2025, Rs. 1.20 million for the year ended March 31, 2026, respectively representing the revenues relating to lab setup services provided under SCA, the costs of fulfilling the contract and the right to charge the customer for the services to be rendered, respectively. <br /> 6.a) Pursuant to Vimta Labs Employee Stock Option Plan 2021 (VLESOP-2021), the nomination and remunerations committee has granted 40500 options to the eligible employees during its meeting held on July 20, 2026. <br /> b) In respect of stock options granted pursuant to the Companys stock option plan, the fair value of the options is accounted as employee compensation expense over the vesting period. Consequently, the amount of employee benefits expense includes Rs. 8.46 million for the quarter ended June 30, 2026, Rs. 6.87 million for the quarter ended March 31, 2026, Rs. 15.19 million for the quarter ended June 30, 2025, Rs. 49.86 million for the year ended March 31, 2026 respectively. <br /> 7.Pursuant to the implementation of the new labour code effective from 21st November, 2025 by the Government of India, the Company has reassessed the impact of the changes based on actuarial valuation and recognised an incremental impact of past service cost in gratuity amounting to Rs.16.16 million, arising primarily from the revision in the definition of wages. Considering its non-recurring nature and quantum involved, past service cost is presented under exceptional items in the statement of profit & loss for the year ended March 31, 2026. <br /> 8. The company does not have any subsidiary/associate/joint venture entity(ies) during the quarter under review and the comparable periods. <br /> 9.The figures of the quarter ended March 31, 2026 are the balancing figures between Audited figures in respect of the financial year ended March 31, 2026 and Unaudited published year to date figures up to the 9 months ended December 31, 2025, which were subjected to limited review by the statutory auditors <br /> 10.The previous period figures have been regrouped/rearranged wherever necessary to make it comparable with the current period.Other Expenses196710000Re-measurement of net defined benefit liability-200000-200000-500000-150000